ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1218

Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort

Gabriella Lui1, Namrata Singh2, James Andrews3, Jonathan Graf4 and Katherine Wysham5, 1University of Washington Department of Bioengineering, Seattle, WA, 2University of Washington, Bellevue, WA, 3University of Washington, Seattle, WA, 4Ucsf, San Francisco, CA, 5VA Puget Sound/University of Washington, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Disease Activity, rheumatoid arthritis, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Single biomarkers have limited utility to date in guiding clinical care in RA. There is growing interest in applying machine learning algorithms to combine demographic, clinical, and biomarker data to better identify and stratify RA patient outcomes. We aimed to determine if unsupervised machine learning methods can be employed in a racially and ethnically diverse RA cohort to identify clusters of patients with different disease activity trajectories, as measured by DAS28ESR.

Methods: Data are derived from the longitudinal, observational University of California, San Francisco RA Cohort from years 2011-2018. Along with routine labs, medication use and disease activity assessments, a multiple biomarker of disease activity (MBDA) panel was obtained at each clinical encounter. The MBDA measures 12 unique serum biomarkers. All observations were collapsed to create a cross-sectional dataset before clustering. Missing data were imputed using multiple imputation with chained equations. Data were standardized in preparation for clustering. Patient clusters were identified by unsupervised K-prototype clustering. Longitudinal disease activity (DAS28ESR) trajectories and 95%CIs were plotted for each cluster. Lasso regression was used to identify biomarkers independently associated with DAS28ESR within the whole cohort and by cluster.

Results: Three distinct clusters were identified in our dataset. Cluster 1 (C1) was our smallest cluster (N=56, 20%), with the oldest age (59±14.4), highest proportion of Hispanic/Latino participants (n=43, 77%), the longest disease duration (11.4±8.9) and highest proportion of biological DMARD exposure (N=41, 73%) (Table 1). C1 also had the highest disease activity measured by DAS28ESR of 5.4±0.8. C2 and C3 both had 109 (40%) participants with similar ages 55.2±12.5 and 54.0±14.0, respectively. C3 had the highest proportion of Asian participants of the clusters (N=91, 33%) and the highest BMI of the cohort at 31.8±7.4. Notably, C2 had the lowest DAS28ESR of 3.2±0.7 (Figure 1). C1 had the highest mean DAS28ESR trajectory over time, whereas C3 had high disease activity that decreased over time. C2 had the lowest disease activity throughout the observation period. CRP and matrix metalproteinase-3 (MMP3) both had significant positive associations with DAS28ESR in our lasso regression model of the whole cohort (Table 2). No significant biomarker associations with DAS28ESR were found in C1. IL-6 had a negative association with DAS28ESR in C2 whereas IL-6 had a positive association and TNF-receptor inhibitor had a negative association with DAS28ESR in C3.

Conclusion: Using machine learning methods, we identified 3 clusters of patients in a racially and ethnically diverse longitudinal RA cohort. Each cluster had distinct disease activity trajectories and biomarker associations. This project demonstrated that machine learning methods can be applied to a moderate size RA cohort. Future work will be focused on evaluating baseline data to predict disease activity overtime and validating our findings in an external cohort.

Cluster table1.jpeg”Table 1

Cluster fig 1.jpeg”Figure 1

Cluster table2.jpeg”Table 2


Disclosures: G. Lui, None; N. Singh, None; J. Andrews, None; J. Graf, None; K. Wysham, None.

To cite this abstract in AMA style:

Lui G, Singh N, Andrews J, Graf J, Wysham K. Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/unsupervised-clustering-identifies-unique-subsets-of-patients-in-a-racially-and-ethnically-diverse-rheumatoid-arthritis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unsupervised-clustering-identifies-unique-subsets-of-patients-in-a-racially-and-ethnically-diverse-rheumatoid-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology